Open-label Roll-Over Study to Assess the Long-term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2016 Status changed from not yet recruiting to recruiting.
- 10 Aug 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.